【摘要】 目的评价利福昔明对急性细菌性肠道病原菌的体外抗菌活性。方法采用肉汤倍比稀释法测定利福昔明和环丙沙星对177株肠道病原菌的最低抑菌浓度(MIC)。结果63株金黄色葡萄球菌对利福昔明的MIC范围为0.03~2.0mg/L,MIC50和MIC90分别为0.06mg/L、0.125mg/L,环丙沙星MIC范围为0.06~64.0mg/L,MIC50和MIC90分别为1.0mg/L、16.0mg/L;肠道革兰阴性病原菌利福昔明MIC范围为2.0~32.0mg/L,MIC50和MIC90分别为8.0mg/L、16.0mg/L,环丙沙星MIC范围为0.125~64.0mg/L,MIC50和MIC90分别为1.0mg/L、16.0mg/L。结论利福昔明对金黄色葡萄球菌有较高的抗菌活性,可作为金黄色葡萄球菌肠炎的首选药物。对于革兰阴性肠道病原菌虽体外抗菌活性不高,但因它有口服不易吸收的特点可以原形由粪便排出,在肠道内充分发挥其抗菌作用。更多还原

【Abstract】 Objective To Value Rifaximin in vitro bacteria activity against enteropathogens with actite enteroinfection.Methods Drug sensitivity test used broth double dilution method to detect 177 enteropathogens’ minimum inhibiting concentration.Results The MIC of Rifaximin against 63 strains staphylococcus aureus were 0.03-2.0mg/L,MIC₅₀ and MIC₉₀ were 0.06mg/L,0.125mg/L.The MIC of Ciprofloxacin were 0.06-64.0mg/L,MIC₅₀ and MIC₉₀ were 1.0mg/L,16.0mg/L.The MIC of Rifaximin against gram negative enteropathogens were 2.0-32.0mg/L,MIC₅₀ and MIC₉₀ were 8.0mg/L,16.0mg/L,MIC of Ciprofloxacin were 0.125-64.0mg/L,MIC₅₀ and MIC₉₀ were 1.0mg/L,16.0mg/L.Conclusion Rifaximin in vitro bacteria activity against staphyloccocus aureus are higher,it is the best drug to treat enteroinfection with staphylococcus aureus.Although Rifaximin in vitro bacteria activity against gram negative enteropathogens are lower,but it has some antibacterial activity in enterotract with its intestinal absorption and exclution from faces.更多还原